Vitamin B6's role in enhancing immune cell function against pancreatic cancer
Vitamin B6 Modulates NK Cell Metabolism in Pancreatic Cancer
['FUNDING_R37'] · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · NIH-10881691
This study is looking at how vitamin B6 might help special immune cells called natural killer (NK) cells work better against pancreatic cancer, with the hope of finding new ways to improve treatment for patients.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR (nih funded) |
| Locations | 1 site (OKLAHOMA CITY, UNITED STATES) |
| Trial ID | NIH-10881691 on ClinicalTrials.gov |
What this research studies
This research investigates how vitamin B6 affects the metabolism of natural killer (NK) cells, which are crucial for targeting and destroying pancreatic cancer cells. By understanding the metabolic needs of NK cells in the nutrient-poor environment of pancreatic tumors, the study aims to enhance the effectiveness of NK cell therapies. The researchers will explore how vitamin B6 scarcity impacts NK cell function and their ability to combat cancer. This could lead to innovative treatment strategies that improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who may benefit from novel immunotherapy approaches.
Not a fit: Patients with other types of cancer or those who are not eligible for NK cell therapies may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for pancreatic cancer by enhancing the immune response against tumor cells.
How similar studies have performed: While NK cell therapies have shown promise in other cancers, the specific approach of modulating NK cell metabolism with vitamin B6 in pancreatic cancer is relatively novel and has not been extensively tested.
Where this research is happening
OKLAHOMA CITY, UNITED STATES
- UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR — OKLAHOMA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MEHLA, KAMIYA — UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- Study coordinator: MEHLA, KAMIYA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology